Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

RVT-101 for Mild to Moderate Alzheimer's Disease with Donepezil (MINDSET)

Start: October 2015
End: September 2017
Enrollment: 1150

What Is This Study About?

This clinical trial will test the experimental drug RVT-101 as an add-on treatment to donepezil in people with mild to moderate Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 85 Years

Must have:

  • Alzheimer's disease
  • Mini-Mental State Examination score of 12-24 at screening or 10-26 at initial visit
  • Hachinski Ischaemia score of 4 or less at screening
  • Women must be of non-childbearing potential, surgically sterile, or willing to use adequate birth control; men who are sexually active will also be required to use adequate birth control
  • Ability to comply with cognitive and other testing
  • Reliable caregiver who can report on subject's status 

Must NOT have:

  • Non-Alzheimer's cause of dementia, for example, diagnosis of vascular dementia
  • Unusual clinical features or clinical course of dementia that suggests alternate dementia diagnosis, including frontotemporal dementia or Lewy body dementia
  • History of significant psychiatric illness, such as schizophrenia or bipolar affective disorder
  • Any clinically relevant disease that makes the subject unsuitable for the study

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Who Is the General Study Contact?

For more information about this clinical trial, visit or contact Axovant Clinical Trials at 646-495-8197 or mindset@axovant.comPlease refer to this study by its identifier, NCT02585934.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Axovant Sciences, Ltd.

Source: ID: NCT02585934

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health